NEW YORK (GenomeWeb) – Swedish drug discovery firm Pelago Bioscience and German proteomics firm OmicScouts today announced a collaboration to determine and quantify drug interactions using Pelago's cellular thermal shift assay (CETSA) technology.

Under the terms of the agreement, Pelago has licensed its CETSA technology to OmicScouts for mass spectrometric and proteomic applications for contract research projects. The firms will combine expertise and resources to offer target identification and validation services.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.